Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...
RAHWAY, N.J. - Merck & Co ., Inc. (NYSE:MRK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its pneumococcal ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
GlobalData on MSN2d
MSD halts Winrevair trial due to success of previous studyMSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback